Abstract: The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and/or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

Abstract: The present invention concerns novel specific iron-activable nitrogen-containing derivatives of salinomycin and narasin, their synthesis and their uses in therapy notably for the treatment of cancer. Also disclosed are pharmaceutically acceptable mediums and medicaments for preventing and/or treating cancer, and/or for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

Abstract: The present invention relates to SMIFH2 derivative compounds and their use as inhibitor of interferon-? mediated signaling. In particular, the invention relates to compounds of general formula (I), and their use as inhibitor of interferon-? mediated signaling, preferably for use for preventing and/or treating diseases associated to the hyper-activation of interferon-? mediated JAK/STAT signaling.

Abstract: Inventors have shown that salinomycin and its derivatives such as AM23, through lysosomal iron accumulation, reduced proliferation/survival of uveal melanoma cells harboring different genetic background. Accordingly, salinomycin and its derivates ironomycin represent valuable therapeutic strategies to treat melanoma and uveal melanoma. The present invention relates to a method for treating melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of an iron metabolism disruptor.

Abstract: The present invention relates to nitrogen-containing derivatives of salinomycin having the formula (I), as well as pharmaceutically acceptable salt thereof, and synthesis and uses thereof, in particular for the treatment and/or prevention of cancer including for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

Abstract: The present invention relates to molecules having the following chemical structure (I). The present invention concerns molecules, in particular active as BRAG2 inhibitors and applications thereof. In particular, the invention concerns BRAG2 inhibitors in the treatment of a cancer or angiogenesis.

Abstract: The present invention relates to novel serotonin derivatives of formula (I): or a pharmaceutically acceptable salt and/or solvate thereof. Another object of the present invention relates to the use of compound of formula (I) as a drug, in particular in the prevention and/or the treatment of iron overload-associated disorders.

Abstract: A sound attenuation material includes a plurality of particles, each having a core and an elastic or compliant coating around the core, and a matrix surrounding the plurality of particles, the matrix being less dense than the core. A method of manufacturing sound attenuating materials includes adding an elastic or compliant coating to core particles and drying and/or curing the coating, mixing the coated core particles into a matrix material, and pouring the mixture into a mold. The core particles are denser than the matrix material.

Abstract: The present invention relates to compounds comprising two biguanidyl radicals that can be useful as anti-inflammatory agent, and also to new compounds comprising two biguanidyl radicals and their use as a drug, in particular for treating a cancer, a metabolic disease, a secondary mitochondrial disorder due to copper overload including Indian childhood cirrhosis, Wilson's disease and Idiopathic infantile copper toxicosis or due to iron overload, an infection by a virus such as a coronavirus or an influenza virus, a neurodegenerative disease or disorder and aging.

Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).

Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of Cytokine Release Syndrome (CRS). The invention also relates to methods for the diagnosis of patients suffering from Cytokine Release Syndrome. The inventors investigate iron homeostasis and the role of CD44-mediated iron endocytosis in the severe inflammatory response and Cytokine Release Syndrome, particularly in SARS-CoV-2 patients. The inventors demonstrate that during activation of M1 macrophages, iron endocytosis is upregulated in a CD44-dependent manner and that CD44 protein levels increase. This effect is specific to M1 macrophages, whereas levels of the canonical iron endocytosis protein TfR1/CD71 remain unchanged. In the present invention, the inventors provide in vitro evidences towards a direct role of CD44-mediated iron endocytosis in the severe inflammatory response such as Cytokine Release Syndrome observed in SARS-CoV-2 patients.

Abstract: The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.

Abstract: The invention relates to the use of an iron-score based on the expression level of at least 1 gene, in particular at least 3, preferably at least 5, and even preferably 8 genes selected in the group consisting of APEX1, TFRC, HIF1A, ABCG2, SCARA3, IREB2, SFXN4 and SLC39A14 involved in the iron metabolism, as a prognosis marker in subjects having MCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

Abstract: A sound attenuation material includes a plurality of particles, each having a core and an elastic or compliant coating around the core, and a matrix surrounding the plurality of particles, the matrix being less dense than the core. A method of manufacturing sound attenuating materials includes adding an elastic or compliant coating to core particles and drying and/or curing the coating, mixing the coated core particles into a matrix material, and pouring the mixture into a mold. The core particles are denser than the matrix material.

Abstract: The present invention relates to molecules having the following chemical structure (I). The present invention concerns molecules, in particular active as BRAG2 inhibitors and applications thereof. In particular, the invention concerns BRAG2 inhibitors in the treatment of a cancer or angiogenesis.

Abstract: A sound attenuation material includes a plurality of particles, each having a core and an elastic or compliant coating around the core, and a matrix surrounding the plurality of particles, the matrix being less dense than the core. A method of manufacturing sound attenuating materials includes adding an elastic or compliant coating to core particles and drying the coating, mixing the coated core particles into a matrix material, and pouring the mixture into a mold. The core particles are denser than the matrix material.

Abstract: The present invention relates to new compounds of formula (I), and their uses.

Abstract: A computing device includes at least one sensor configured to generate voltage signals indicative of a measured neurological impulse and one or more application specific integrated circuit (ASIC) chips connected to the at least one sensor. The one or more ASIC chips configured to determine at least one command for operating a device based on the measured neurological impulse and to transmit the at least one command to the device.

Abstract: A waste material improvement and reuse method involves identifying an available material having a crush resistance that does not meet a requirement for use as proppant, but which can be improved to meet the requirement, and modifying a surface of the available material to improve the crush resistance to meet the requirement by applying a binding agent and/or an encapsulating agent to the available material, forming clumps of particles of the available material and increasing crush resistance.